GT Biopharma, Inc. (NASDAQ:GTBP) Sees Large Growth in Short Interest

GT Biopharma, Inc. (NASDAQ:GTBP) was the recipient of a significant increase in short interest in the month of December. As of December 31st, there was short interest totaling 2,111,313 shares, an increase of 45.3% from the December 15th total of 1,453,242 shares. Currently, 20.6% of the shares of the company are sold short. Based on an average trading volume of 2,660,073 shares, the days-to-cover ratio is currently 0.8 days. Based on an average trading volume of 2,660,073 shares, the days-to-cover ratio is currently 0.8 days. Currently, 20.6% of the shares of the company are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in GT Biopharma stock. SeaCrest Wealth Management LLC purchased a new position in GT Biopharma, Inc. (NASDAQ:GTBP) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 50,000 shares of the company’s stock, valued at approximately $37,000. SeaCrest Wealth Management LLC owned about 0.47% of GT Biopharma as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 8.15% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on GTBP. Wall Street Zen downgraded GT Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, September 20th. Weiss Ratings reissued a “sell (e)” rating on shares of GT Biopharma in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

GT Biopharma Stock Up 2.2%

NASDAQ GTBP traded up $0.02 on Friday, hitting $0.75. The stock had a trading volume of 2,047,012 shares, compared to its average volume of 2,150,146. The company’s 50-day moving average is $0.73 and its two-hundred day moving average is $1.05. GT Biopharma has a one year low of $0.54 and a one year high of $3.85. The stock has a market cap of $7.94 million, a price-to-earnings ratio of -0.22 and a beta of 1.17.

GT Biopharma (NASDAQ:GTBP) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.45). On average, sell-side analysts anticipate that GT Biopharma will post -6.79 earnings per share for the current year.

About GT Biopharma

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).